Fig. 5From: Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trialThe 52-week disease-free survival (DFS) in patients with malignant haematological diseases after enrolment stratified according to the MSC group and control groupBack to article page